BackKrystal Biotech Overview

Krystal Biotech Receivables

Track Krystal Biotech's receivables ($130M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$127.02M
23.01% YoYΔ $23.76M vs prior year quarter

Peer average

Loading

Krystal Biotech Receivables History

Loading

Krystal Biotech vs. peers: Receivables Comparison

Loading

Krystal Biotech Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Krystal Biotech (KRYS) FAQ

As of the most recent data (March 2026), KRYS shows a receivables of $130M. That compares with $100M in the prior-year period — up 23.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KRYS's receivables is now $130M (was $100M) — a 23.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Krystal Biotech is outperforming or lagging.

Tracking KRYS's receivables over time shows whether Krystal Biotech is scaling, shrinking, or reshaping that part of the business. The current reading is $130M That compares with $100M in the prior-year period — up 23.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Krystal Biotech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $130M) with ownership activity and broader fundamentals.

Krystal Biotech's receivables is $130M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.